IKT (Inhibikase Therapeutics) GF Score: 33/100 (As of Jul. 04, 2026) — 38% Above Median


IKT Inhibikase Therapeutics Inc IKT
33 GF Score
Price $1.99
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics GF Score?

Inhibikase Therapeutics IKT +3.11% 33 GF Score is 33 as of Jul. 04, 2026, which is 38% above its 10-year median of 24.00. GuruFocus rates IKT with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Inhibikase Therapeutics has the GF Score of 33, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 10/10
2. Profitability Rank : 2/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Inhibikase Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Inhibikase Therapeutics  (NAS:IKT) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Inhibikase Therapeutics GF Score Related Terms

IKT vs FHTX, OBIO, FULC: GF Score Comparison

For the Biotechnology subindustry, Inhibikase Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's GF Score falls into.


IKT
33GF Score
Inhibikase Therapeutics Inc IKT
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 33 mean?
Inhibikase Therapeutics (IKT) has a GF Score of 33 as of Jul. 04, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Inhibikase Therapeutics and its competitors. This is 38% above median its historical median of 24.00. Over the past decade, Inhibikase Therapeutics' GF Score has ranged from 7.00 to 42.00.
Is Inhibikase Therapeutics' GF Score too high?
Inhibikase Therapeutics' current GF Score of 33 is 38% above median its 10-year median of 24.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 42.00. Overall, Inhibikase Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' GF Score compare to FHTX and OBIO?
Inhibikase Therapeutics' GF Score of 33 can be compared against companies in the Biotechnology industry. Historically, Inhibikase Therapeutics' own GF Score has ranged from 7.00 to 42.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current GF Score is 33, which is 38% above median its own 10-year median of 24.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current GF Score of 33. The current GF Score is 33, which is 38% above median its 10-year median of 24.00. Inhibikase Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current GF Score is 33 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
33GF Score

Get the complete analysis for IKT

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price